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Novel treatment strategies have remarkably improved the multiple myeloma (MM) 
patients’ survival, with associated increased costs. A joint panel meet of international 
experts from India and Ukraine was held in New Delhi on May 19, 2016 focusing on 
MM management, bortezomib role, unmet medical needs, and current challenges. The 
health-care system for oncology in India is majorly private vs. government-based in 
Ukraine. In India, electrophoresis, serum-free light chain assays, bone marrow tests, and 
X-rays are available modes of diagnosis. Despite of the numerous cancer centers and 
stem cell transplant centers, most patients do not prefer transplant owing to its high-cost 
and social stigma. Majority of the patients are treated with bortezomib or lenalidomide-
based regimens. Most patients buy drug themselves. The expanding generic drugs 
market is a ray of hope for the affordable drugs. In Ukraine, immuno-fixation, bone 
marrow analysis, and magnetic resonance imaging are common diagnostic modalities. 
Due to high cost, only few patients undergo transplant. Bortezomib-based regimens 
are preferred in most of the patients; however, usage is limited due to high costs and 
lack of funds. Thalidomide-based regimens are used for maintenance therapy due to 
affordability. In case of relapsed MM, bortezomib is preferred in triple therapy; however, 
more affordable option is cyclophosphamide, thalidomide, and dexamethasone 
(CTD). Issues, such as cost containment, common treatment strategies, enhanced 
collaboration, and improved health-care access, need immediate attention. High-quality 
generics access will improve outcomes and support health-care cost containment. 
Pharmacoeconomic studies and head-to-head trials are warranted to determine the 
cost-effectiveness and benefit of novel therapies in MM.
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iNtrODUctiON
Multiple myeloma (MM) is a heterogeneous disorder which accounts for 10% of hematological 
cancers (1). Incidence of MM was found to be 2.1 (per 100,000 of people) in Ukraine, which is much 
lesser than in the United States (4.3) and Europe (4.1) (2) and almost on par with incidence in India, 
i.e., 1.2–1.8 per 100,000 of people (3).
taBle 1 | National comprehensive cancer Network (NccN) Guidelines (7).
Preferred regimens Other regimens
Primary therapy for transplant 
candidates (assess for response after 
2 cycles)
Bortezomib/dexamethasone (category 1)
Bortezomib/cyclophosphamide/dexamethasone
Bortezomib/doxorubicin/dexamethasone (category 1)
Bortezomib/lenalidomide/dexamethasone
Bortezomib/thalidomide/dexamethasone (category 1)
Lenalidomide/dexamethasone (category 1)
Carfilzomib/lenalidomide/dexamethasone
Dexamethasone (category 2B)
Ixazomib/lenalidomide/dexamethasone
Liposomal doxorubicin/vincristine/dexamethasone (DVD) 
(category 2B)
Thalidomide/dexamethasone (category 2B)
Primary therapy for non-transplant 
candidates (assess for response after 
2 cycles)
Bortezomib/dexamethasone
Bortezomib/cyclophosphamide/dexamethasone
Bortezomib/lenalidomide/dexamethasone (category 1)
Lenalidomide/low-dose dexamethasone (category 1)
Melphalan/prednisone/bortezomib (MPB) (category 1)
Melphalan/prednisone/lenalidomide (MPL) (category 1)
Melphalan/prednisone/thalidomide (MPT) (category 1)
Dexamethasone (category 2B)
Ixazomib/lenalidomide/dexamethasone
Liposomal doxorubicin/vincristine/dexamethasone (DVD) 
(category 2B)
Melphalan/prednisone (MP)
Thalidomide/dexamethasone (category 2B)
Vincristine/doxorubicin/dexamethasone (VAD) (category 2B)
Maintenance therapy Bortezomib
Lenalidomide (category 1)
Thalidomide (category 1)
Bortezomib + prednisone (category 2B)
Bortezomib + thalidomide (category 2B)
Interferon (category 2B)
Steroids (category 2B)
Thalidomide + prednisone (category 2B)
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There has been a remarkable improvement in the survival 
of MM patients in the last decades. This clinical progress was 
attributed to the availability of novel and target specific approach 
to treatment – proteasome inhibitors and immunomodulators 
(iMiDs), such as thalidomide, lenalidomide, and bortezomib and 
autologous stem cell transplantation (ASCT) (2).
Multiple myeloma poses a significant health-care challenge 
from both cost and quality of care perspective. In the US, the 
cost of MM is attributed to almost 9–10% of total cancer care 
costs. The rapidly increasing trend in costs is due to the develop-
ment of novel agents, new diagnostic and treatment modalities, 
aging, and expanding populations, and increasing health-care 
costs (4).
Bortezomib, a first in class protease inhibitor (PI) was approved 
in 2003 for the treatment of progressive MM in patients who 
had received at least two prior therapies. In combination with 
melphalan and prednisone, it is also indicated for the treatment 
of adult patients with previously untreated MM who are not 
eligible for high-dose chemotherapy with hematopoietic stem cell 
transplantation. Currently, it has been recommended for primary 
induction therapy and also for consolidation and salvage therapy 
post relapse (5).
Since its development, bortezomib has come a long way 
in treating MM patients. Its wider therapeutic spectrum rang-
ing from frontline induction to maintenance therapy has been 
increasingly explored in studies with the goal of achieving deeper 
responses, longer progression free survival (PFS), and possibly 
overall survival (OS). Bortezomib, in combination with other 
drugs, can also be reused in relapse setting (6).
Novel drugs, such as carfilzomib, Ixazomib, and poma-
lidomide, have also been introduced lately, leading to the bright 
future of MM patients. A few more drugs with novel mechanisms 
of action are under testing phase in clinical trials.
These drugs are used either alone or as a part of combination 
regimen to demonstrate substantial activity in terms of higher 
complete response (CR) rates than previous standard regimens.
There are several aspects, which need to be considered in 
the management of MM. A common treatment algorithm to 
standardize treatment worldwide, cost reduction for emerging 
treatment strategies, uniform adaptation of treatment guidelines, 
country-wide variations in outcome of MM, need for better care, 
and improved communication among treatment providers are 
some of these aspects. The concept of clonal diversity among 
patients needs attention while deciding the MM therapies. 
Moreover, there is an unmet medical need for more treatment 
options in relapsed or refractory disease, extramedullary disease, 
and those with high-risk cytogenetic profiles (4).
To address such issues, there is a need for collaborative 
effort. In this regard, a joint panel meet of international experts 
was held in New Delhi on May 19, 2016. Various experts in 
hematology and oncology were invited from India and Ukraine 
to share experiences from their respective countries in the 
management of MM, with special emphasis on the role of 
bortezomib in MM.
This paper reflects the management in MM patients, usher-
ing toward the role of bortezomib alone or in combination with 
other drugs. The paper also focusses on analysis from various 
trials and discussing their implications in clinical practice. 
It  briefs about the challenges, unmet medical needs discussed 
in the experts meeting, and finally discusses the management 
strategies followed in Ukraine, the differences from practices in 
India, with the current challenges faced by the physicians and 
patients in these developing countries.
rOle OF BOrteZOMiB iN MUltiPle 
MYelOMa
The management of MM patients and the choice of therapy (cat-
egory 1 or category 2A drugs) as per the National Comprehensive 
Cancer Network (NCCN) guidelines (7) (Table 1) was an impor-
tant point of discussion in the meeting. There was also a brief 
discussion on the key trials conducted on bortezomib (Table 2).
taBle 2 | selected trials discussed in the meeting.
clinical studies treatment arms sample size  
(no. of patients)
Primary efficacy measures
Bortezomib: key clinical trials in previously untreated MM patients
VISTA TRIAL (11) (Phase 3 study) BTZ 1.3 mg/m2 + MP vs. MP alone 682 TTP: 24.0 months (BTZ + MP)
TTP: 16.6 months (MP alone)
IFM 2005-01 (12) (Phase 3 study) VD (BTZ 1.3 mg/m2 + DEX 40 mg) vs. VAD 482 Post induction CR/nCR: 14.8% (VD)
Post induction CR/nCR: 6.4% (VAD)
GIMEMA Italian Myeloma Network (13)  
(Phase 3 study)
VTD (BTZ 1.3 mg/m2 + THAL + DEX 40 mg) vs. TD 480 Post induction CR/nCR: 31% (VTD)
Post induction CR/nCR: 11% (TD)
HOVON-65/GMMG-HD4 (14)  
(Phase 3 study)
PAD (BTZ 1.3 mg/m2 + DOX + DEX 40 mg) vs. VAD 827 PFS: 35 months (PAD)
PFS: 28 months (VAD)
Bortezomib: key clinical trials in relapsed/refractory multiple myeloma (rrMM)
SUMMIT (Phase 2 study) (15) BTZ 1.3 mg/m2 193 ORR: 35%
CREST (16) (Phase 2 study) BTZ 1.3 mg/m2 54 ORR: 50% (1.3 mg/m2)
BTZ 1.0 mg/m2 ORR: 33% (1.0 mg/m2)
APEX TRIAL (17) (Phase 3 study) BTZ 1.3 mg/m2 vs. high-dose DEX 40 mg 669 TTP: 6.22 months (BTZ)
TTP: 3.49 months (high-dose DEX)
Pegylated liposomal doxorubicin +  
bortezomib (Phase 3 study) (18)
PLD 30 mg/m2 + BTZ 1.3 mg/m2 vs. BTZ 1.3 mg/m2 646 TTP: 9.3 months (PLD + BTZ)
TTP: 6.5 months (BTZ)
VISTA, Velcade as initial standard therapy in multiple myeloma: assessment with melphalan and prednisone; BTZ, bortezomib; MP: melphalan, prednisolone; TTP, time to 
progression; DEX, dexamethasone; VAD, vincristine, adriamycin, dexamethasone; CR/nCR, complete response/near complete response; THAL, thalidomide; DOX, doxorubicin; 
SUMMIT, study of uncontrolled multiple myeloma managed with proteasome inhibition therapy; CREST, clinical response and efficacy study of bortezomib in the treatment of 
relapsing multiple myeloma; APEX, assessment of proteasome inhibition for extending remissions; ORR, overall response rate; PLD, pegylated liposomal doxorubicin.
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The treatment strategy is based on NCCN guidelines in 
India. For the diagnosis and treatment of MM in Ukraine, 
system of international guidelines [British Committee for 
Standards in Hematology (BCSH) (8), European Society for 
Medical Oncology (ESMO) (9), and NCCN guidelines (7)] was 
incorporated into Ukrainian National Guideline at the end of 
year 2015 (10). The treatment algorithm for the management 
of MM according to national requirements is as depicted in the 
Figure 1A.
Currently routine MM management in Ukraine could vary 
and differ from guideline due to limitations in health-care 
resources.
MaNaGeMeNt OF MUltiPle MYelOMa: 
assOciateD cHalleNGes aND 
liMitatiONs
Management of MM in developing economies was another point 
of interest in the meeting.
Ukraine (10, 19) and indian scenario
Access to Healthcare and Optimal Treatment
In Ukraine, almost equal proportion of the MM cases are treated 
at hematology and oncology centers, respectively. Physicians 
diagnose MM at primary and secondary health-care levels 
according to National Guideline. MM cases are registered in 
“National Cancer Registry of Ukraine” or “Indices of Work of 
Hematological Service in Ukraine.”
In contrast, majority of the health-care system for oncology 
is private in India. Although some of the government set-ups are 
available, most of the patients have to buy drug on their own.
Availability of Diagnostics and Treatment Drugs
Diagnostics
As per the order of Ministry of Health of Ukraine (10), each 
patient needs to be diagnosed and treated as per the standard 
procedure.
For diagnosis, X-ray, computed tomography (CT), and mag-
netic resonance imaging (MRI) are easily available. However, 
there are only three centers for positron emission tomography 
(PET), four centers for serum/urine immuno-fixation and serum/
urine protein electrophoresis, three for cytogenetics, and one for 
free light chain (FLC) assay. All these tests are associated with 
high costs. Immuno-fixation, bone marrow analysis, and MRI are 
commonly used modes of diagnosis. PET is not used much often 
due to high cost factors.
There is only one transplant center in Ukraine for patients who 
require transplantation. The transplant cost for MM in Ukraine is 
high, which is unaffordable by patients with lack of state support.
In India, most centers have the availability of serum/urine elec-
trophoresis, serum FLC assays, bone marrow, and X-ray survey. 
Some centers may not have facilities for serum β2-microglobulin. 
Facilities for fluorescence in  situ hybridization (FISH) test are 
not available routinely in most centers (20). Most of the patients 
do not go for transplant because of its high cost, fear, and social 
stigma.
A leading Professor of Medical Oncology, Dr. Lalit Kumar, in 
one of his interview told that in All India Institute of Medical 
Sciences (AIIMS), Delhi, which is funded by central government, 
the cost of transplant is less than INR 300,000 (i.e., 6,000 US 
$). Private hospital charges approximately INR 800,000 (i.e., 
16,000 US $) (20). There are 25 regional cancer centers, and 
more than 15 centers in India which are doing regular stem 
cell transplants (21).
FiGUre 1 | (a) Treatment algorithm according to National Guidelines (Ukraine) (10). 
(Continued)
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Treatment Options in MM Patients in Ukraine
There is not sufficient funding for affording first-line treatment 
drugs, thus various treatment options, such as thalidomide and 
bortezomib, are preferred. Bortezomib usage is less due to high 
cost and lack of funds. Only 20–30% patients are funded by the 
official program for buying these drugs. Thalidomide is affordable 
and presently available also as maintenance therapy in Ukraine. 
Lenalidomide and bortezomib are more commonly used world-
wide than thalidomide.
The choice of treatment in different categories of patients is as 
mentioned below:
  Transplant eligible patients: vincristine, doxorubicin, and dex-
amethasone (VAD) are still used in some transplant eligible 
FiGUre 1 | continued  
*ASCT, autologous stan cell transplantation; VGPR, very good partial response; HDCT, high-dose chemotherapy. Currently, routine MM management in Ukraine 
could vary and differ from guideline due to limitations in health care resources. (B) Cost of imatinib brand Gleevac (gray bars) and cost of generic imatinib per patient 
per month (black bars). Source: MSF-India 2013. (c) U.S. Statin market share before and projected market share after the entry of Generic Atorvastatin. Data for 
2002 through 2009 are from IMS Health National Prescription Audit.
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patients in Ukraine. However, bortezomib/thalidomide-based 
regimens, such as DVD (pegylated liposomal doxorubicin, 
bortezomib, and dexamethasone), thalidomide, cyclophos-
phamide, dexamethasone (TCD), PAD (bortezomib, doxo-
rubicin, dexamethasone), VTD (bortezomib, thalidomide, 
dexamethasone) etc., are mostly preferred.
  Transplant ineligible patients: melphalan, prednisolone 
(MP), high dose of dexamethasone, high-dose MP, VMP 
(bortezomib, melphalan, prednisolone), VAD, and VTD are 
preferred.
  In elderly: low-dose MP, low-dose dexamethasone, TCD, and 
VCD (bortezomib, cyclophosphamide, dexamethasone) are 
preferred.
  Relapsed and refractory patients: the management is chal-
lenged by availability of drugs. Mainly three drugs are used 
upfront (cyclophosphamide, dexamethasone, bortezomib, or 
thalidomide). In case of patients with lower socio-economic 
background, best affordable treatment option is provided. 
Though bortezomib is preferred in triple therapy, the more 
affordable regimen, such as cyclophosphamide, thalidomide, 
and dexamethasone (CTD), may be considered. Patients are 
observed for a long time before starting treatment for relapse 
and treated only if they become symptomatic. At early relapse 
or disease progression on therapy, therapy is changed to 
other, non-cross-resistance, regimens. At late relapse, therapy 
is chosen taking into account duration of patient response 
to treatment, toxicities, and received first-line therapy. The 
following iMiDs are used for relapse treatment: thalidomide, 
lenalidomide; also bortezomib.
Furthermore, in the meeting, there was a brief discussion on 
the 10  years of experience of MM treatment with bortezomib 
at Lviv’s center in Ukraine by Orest Tsyapka, DMS, PhD. He 
stated that “total 59 and 37 patients were assigned to bortezomib 
and thalidomide-based regimens, respectively. Fifteen patients 
received transplant. In 2015, median survival in patients with MM 
was found to be 74 months. Overall survival (OS) and progression 
free survival (PFS) were found to be better with bortezomib as 
compared to thalidomide. Overall survival for naïve patients as 
well as relapsed/refractory patients treated with bortezomib was 
again better than thalidomide. Median survival was found to be 
59 months in the year 2010 in MM patients, which was found to be 
increased to 74 months after the use of bortezomib was started.”
Treatment Options in MM Patients in India
In India, the generics drug market is expanding. Competition 
among generic companies keeps the price lower for these drugs. 
There are many Indian companies producing generic drugs in 
India. However, situation is changing because of patent issues. 
As a result, very few patients can afford newer molecules such as 
pomalidomide and carfilzomib.
Majority of patients are treated with a 3-drugs regimen for 
6–8  months followed by maintenance. However, once these 
patients relapse, it is difficult to treat as majority of drugs are 
already used upfront. Moreover, newer molecules are not avail-
able in India.
Majority of patients in India are treated with bortezomib 
upfront or lenalidomide-based drugs. If a patient has prolonged 
remission, these drugs can be again used in relapse.
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Bortezomib is recommended by NCCN for RRMM: as mono-
therapy, in combination with PEGylated liposomal doxorubicin, 
or with panobinostat plus low-dose dexamethasone. The drug 
results in 55–87% response rates in combination therapies. It 
does not cause resistance even in case of relapse, and thus retreat-
ment with bortezomib is feasible. A retrospective analysis from 
a tertiary care center in Hyderabad, India, in newly diagnosed 
patients suggest that bortezomib is effective and safe as first-line 
therapy in MM patients. The overall response rate, CR, and VGPR 
were found to be 88.5, 31.4, and 34.2%, respectively. Bortezomib 
is effective in reversing renal impairment. The only contraindica-
tion is significant neuropathy in upfront use (22).
Lenalidomide is approved for RRMM based on two parallel 
phase III randomized trials of lenalidomide and dexamethasone 
vs. dexamethasone alone in patients with RRMM showing signifi-
cant improvement in median OS. Lenalidomide and dexametha-
sone are recommended for treatment for RRMM (category 1) in 
NCCN guidelines. About 65–95% response has been observed 
with lenalidomide-based regimens.
Thalidomide is not effective at relapse setting. However, 
it is safe in context of renal failures. It is basically used in 
combination therapies. Clinical benefit rate of about 70% has 
been observed with thalidomide in combination regimens 
with agents, such as vorinostat, bortezomib, or carfilzomib, for 
refractory MM. Pomalidomide is not available in India but has 
deeper response and is safer. Similarly, carfilzomib is also not 
available, which has shown significantly improved median PFS 
in one of the study.
Other points of discussion were:
•	 In India, subcutaneous forms are used more, and higher dose 
is used in subcutaneous than intravenous drugs.
•	 Combination cytotoxic regimens are reasonable as salvage 
therapy. Favorable responses have been observed with combi-
nation of cyclophosphamide with bortezomib, lenalidomide, 
or thalidomide.
•	 Benefit of ASCT in salvage setting is not clear, and thus it 
should not be considered outside clinical trial setting due to 
substantial mortality risk. Benefit of ASCT in salvage setting is 
not clear, and thus it should not be considered outside clinical 
trial setting due to substantial mortality risk.
DiscUssiON
As MM has evolved from acute to chronic disease, there is a 
continuous increase in treatment costs due to longer OS and 
continual care required during remissions and relapses. Novel 
agents, such as immune modulators (iMiDs) and PIs, have 
improved the response rates and survival, but they are given in 
addition to standard treatments. Additional costs of routine diag-
nostics, stem cell transplants, and supportive care further pose a 
tremendous economic burden to the patients and the health-care 
system. These are important aspects to be considered, especially 
in emerging economies where there are lack of proper resources 
and funds (23).
On the basis of most recent published estimates of the aver-
age prices in the US, cost of one 21-day cycle of bortezomib was 
estimated to be $6,450 (3.5 mg vial, quantity 4) or $70,950 per 
patient (11 cycles) (24). These costs vary as per regimen and 
further across countries due to variation in pricing agreements 
and availability of generics (24).
The availability of generic drugs at a comparatively lower 
cost without compromising quality would be an affordable 
option.
For example, the steep decline in imatinib costs per patient 
treatment for chronic myeloid leukemia (CML) per month 
occurred after its patent expiry and entry of generic version in 
the market in various countries (Figure 1B) (25). Similarly, the 
appearance of the generic atorvastatin boosted lipid-lowering 
treatment economic availability in the US after atorvastatin pat-
ent expiry (Figure 1C) (26).
Costs can be reduced further by the use of guideline based 
therapy, targeted therapies, and therapies that offer lower toxicity, 
higher survival, and better quality of life. Appropriate supportive 
care strategies, minimizing hospitalization, and department (ED) 
visits, decreasing the use of medical care at the end of life are the 
other ways of cost containment.
Cost containment is an important goal to reduce this 
burden; however, it should not be the only consideration for 
treatment choice. Quality of care and an optimal outcome 
should be the priority for both the managed care organizations 
and patients.
A few pharmacoeconomic models and studies have been done 
to study the cost-effectiveness.
Garrison et al. conducted a pharmacoeconomic analysis for 
transplant ineligible patients comparing MP with novel regimens, 
such as VMP, melphalan/prednisone/thalidomide (MPT), mel-
phalan/prednisone/lenalidomide (MPR), and MPR-R. The study 
concluded that VMP is likely to be more cost-effective and cost 
saving as compared to other regimens (27).
In case of RRMM, bortezomib is comparatively a more cost-
effective treatment (in terms of cost/life year gained) as compared 
to other available options. It provides an additional life year at 
a cost of $45,356. Also its incremental cost-effectiveness ratio 
(ICER) remains favorable (28).
In two studies done by the investigators in Ukraine, bort-
ezomib was found to be the most economically significant treat-
ment. A retrospecive analysis of the pilot study was performed in 
Ukraine at Kiev center. The average annual total cost of pharma-
cotherapy in MM patients in 2012 was equivalent to 2,297,984 
EUR of which bortezomib had taken the major part of total costs 
(29, 30).
Evaluations of newer, advanced therapies are lacking despite 
their significant contribution in improving quality of life and 
survival of patients and therefore warranted in future.
With the rapidly evolving treatment landscape and forth-
coming options and guidelines, a lot of flexibility is allowed in 
prescribing, as described under NCCN guidelines. Formulating 
clinical pathways using an evidence-based approach in line with 
guidelines might be a good option. This might also reduce local, 
regional, and national variations in practice.
A tremendous effort is required to improve the health-care 
access to the MM patients. Quality cancer care systems should 
be implemented with more defined networking amongst the 
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health-care providers, medical oncologists, hematologists, 
surgeons, etc. and strong decision-support strategies. More trans-
plant or transfusion centers need to be established, and a larger 
number of oncologists and surgeons are required to be added to 
the current pool.
Furthermore, an improved collaboration between all the 
stakeholders, health-care professionals, pharmaceutical industry, 
regulatory agencies, and managed care organizations is the need 
of hour to fill the current gaps in the management of MM in 
emerging or developing nations.
cONclUsiON
Cost reduction, improved healthcare access, enhanced collabo-
ration, and common treatment strategies are few issues, which 
need immediate attention in the management of MM.
The recent advancements in the management of MM and 
possible addition of second- or third-generation PIs and iMiDs 
in the near future will increase the economic burden. Whether 
this increased burden is justified by the health gain produced is 
the question, which needs further investigation through more 
pharmacoeconomic studies and head-to-head trials between 
various agents for determining their cost-effectiveness and 
overall benefit.
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